HMGB1 and hematologic disorder: In summary, HMGB1 systematically drives resistance to platinum agents, anthracyclines, proteasome inhibitors, and targeted therapies in solid and hematological malignancies through a multi‐axis “autophagy‐efflux‐DNA repair‐death inhibition‐epigenetic remodeling” network—providing actionable molecular hubs for reversing therapeutic resistance.